Skip to main content
Erschienen in: Endocrine Pathology 4/2012

01.12.2012

Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome

verfasst von: Daniel A. Winer, Shawn Winer, Lorne Rotstein, Sylvia L. Asa, Ozgur Mete

Erschienen in: Endocrine Pathology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Marfan syndrome (MFS) is an autosomal dominant hereditary disorder of connective tissue associated with perturbations in transforming growth factor β (TGF-β) biology, most often due to mutations in FBN1 gene that encodes fibrillin-1. To our knowledge, there is no known association of MFS with thyroid carcinoma. We report a 46-year-old man with known history of MFS who developed an unusual histological variant of papillary thyroid carcinoma. The tumor exhibited a widely invasive florid papillary growth pattern with prominent long villous fronds. Immunohistochemical and molecular analysis revealed a BRAFV600E mutation, evidence of aggressive biomarker expression (positivity for HBME-1, cytokeratin 19, galectin-3 and cyclin D1, and loss of p27), and changes associated with TGF-β-related epithelial-to-mesenchymal transition with active phospho-SMAD signaling. We introduce a unique histological pattern of papillary thyroid carcinoma that is associated with MFS. The combination of BRAFV600E mutation in the setting of altered TGF-β signaling and weak connective tissue integrity associated with MFS may cooperate and possibly be responsible to form this unique villous morphology with epithelial-to-mesenchymal transition and invasive growth.
Literatur
1.
Zurück zum Zitat Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43:769–787, 2006.PubMedCrossRef Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43:769–787, 2006.PubMedCrossRef
2.
Zurück zum Zitat Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. J Urol 140:80–84, 1988.PubMed Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. J Urol 140:80–84, 1988.PubMed
3.
Zurück zum Zitat Finlay M, Laperriere N, Bristow RG. Radiotherapy and Marfan syndrome: a report of two cases. Clin Oncol (R Coll Radiol) 17:54–56, 2005.CrossRef Finlay M, Laperriere N, Bristow RG. Radiotherapy and Marfan syndrome: a report of two cases. Clin Oncol (R Coll Radiol) 17:54–56, 2005.CrossRef
4.
Zurück zum Zitat Newbold SG, Shafer AD, Goodwin CD., Nanagas VN, and Dimlich SH. Stage III Wilms’ tumor of a solitary kidney in a patient with Marfan’s syndrome: A 5-yr survival. J Pediatr Surg 17:841–842, 1982.PubMedCrossRef Newbold SG, Shafer AD, Goodwin CD., Nanagas VN, and Dimlich SH. Stage III Wilms’ tumor of a solitary kidney in a patient with Marfan’s syndrome: A 5-yr survival. J Pediatr Surg 17:841–842, 1982.PubMedCrossRef
5.
Zurück zum Zitat Kraemer DM, Waschke J, Kunzmann V, Wilhelm M. Veno-occlusive disease in a male patient with Marfan syndrome and common acute lymphoblastic leukemia during induction therapy. Ann Hematol 82:444–447, 2003.PubMedCrossRef Kraemer DM, Waschke J, Kunzmann V, Wilhelm M. Veno-occlusive disease in a male patient with Marfan syndrome and common acute lymphoblastic leukemia during induction therapy. Ann Hematol 82:444–447, 2003.PubMedCrossRef
6.
Zurück zum Zitat Gruber HL, Samuel J. Hamartoma of the heart and carcinoma of the tongue associated with Marfan’s syndrome. J Indian Med Assoc 40:23–28, 1963.PubMed Gruber HL, Samuel J. Hamartoma of the heart and carcinoma of the tongue associated with Marfan’s syndrome. J Indian Med Assoc 40:23–28, 1963.PubMed
7.
Zurück zum Zitat Roopnariane A, Freed RJ, Price S, Fox EJ, Ritty TM. Osteosarcoma in a Marfan patient with a novel premature termination codon in the FBN1 gene. Connect Tissue Res 52:157–165, 2011.PubMedCrossRef Roopnariane A, Freed RJ, Price S, Fox EJ, Ritty TM. Osteosarcoma in a Marfan patient with a novel premature termination codon in the FBN1 gene. Connect Tissue Res 52:157–165, 2011.PubMedCrossRef
8.
Zurück zum Zitat Kondo T, Ezzat S, Asa SL Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306, 2006.PubMedCrossRef Kondo T, Ezzat S, Asa SL Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306, 2006.PubMedCrossRef
9.
Zurück zum Zitat Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2008/​, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
10.
Zurück zum Zitat LiVolsi VA. Papillary carcinoma tall cell variant (TCV): a review. Endocr Pathol 21:12–15, 2010.PubMedCrossRef LiVolsi VA. Papillary carcinoma tall cell variant (TCV): a review. Endocr Pathol 21:12–15, 2010.PubMedCrossRef
11.
Zurück zum Zitat La Perle KM, Jhiang SM, Capen CC Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671–677, 2000.PubMedCrossRef La Perle KM, Jhiang SM, Capen CC Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671–677, 2000.PubMedCrossRef
12.
Zurück zum Zitat Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, Asa SL. Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior. Endocr Pathol 8:21–28, 1997.PubMedCrossRef Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, Asa SL. Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior. Endocr Pathol 8:21–28, 1997.PubMedCrossRef
13.
Zurück zum Zitat Khoo ML, Ezzat S, Freeman JL, Asa SL Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810–1813, 2002.PubMedCrossRef Khoo ML, Ezzat S, Freeman JL, Asa SL Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810–1813, 2002.PubMedCrossRef
14.
Zurück zum Zitat Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814–1818, 2002.PubMedCrossRef Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814–1818, 2002.PubMedCrossRef
15.
Zurück zum Zitat Khoo ML, Freeman JL, Witterick IJ, Irish JC, Rotstein LE, Gullane PJ, Asa SL. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 128:253–257, 2002.PubMed Khoo ML, Freeman JL, Witterick IJ, Irish JC, Rotstein LE, Gullane PJ, Asa SL. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 128:253–257, 2002.PubMed
16.
Zurück zum Zitat Cheng S, Serra S, Mercado M, Ezzat S, Asa SL 2011 A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385–2394, 2011.PubMedCrossRef Cheng S, Serra S, Mercado M, Ezzat S, Asa SL 2011 A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385–2394, 2011.PubMedCrossRef
17.
Zurück zum Zitat Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104:2803–2808, 2007.PubMedCrossRef Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104:2803–2808, 2007.PubMedCrossRef
18.
Zurück zum Zitat Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 1:29, 2011.PubMedCrossRef Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 1:29, 2011.PubMedCrossRef
19.
Zurück zum Zitat Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24:1545–1552, 2011.PubMedCrossRef Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24:1545–1552, 2011.PubMedCrossRef
20.
Zurück zum Zitat Ikushima H, Miyazono K TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10:415–424, 2010.PubMedCrossRef Ikushima H, Miyazono K TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10:415–424, 2010.PubMedCrossRef
21.
Zurück zum Zitat Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943–3949, 2008.PubMedCrossRef Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943–3949, 2008.PubMedCrossRef
22.
Zurück zum Zitat Mizuguchi T, Matsumoto N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 52:1–12, 2007.PubMedCrossRef Mizuguchi T, Matsumoto N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 52:1–12, 2007.PubMedCrossRef
23.
Zurück zum Zitat Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C, Kajii T, Jondeau G, Ohta T, Kishino T, Furukawa Y, Nakamura Y, Niikawa N, Boileau C, Matsumoto N. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855–860, 2007.CrossRef Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C, Kajii T, Jondeau G, Ohta T, Kishino T, Furukawa Y, Nakamura Y, Niikawa N, Boileau C, Matsumoto N. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855–860, 2007.CrossRef
24.
Zurück zum Zitat Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30:3153–3162, 2011.PubMedCrossRef Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30:3153–3162, 2011.PubMedCrossRef
25.
Zurück zum Zitat Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86–93, 2010.PubMedCrossRef Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86–93, 2010.PubMedCrossRef
26.
Zurück zum Zitat Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317–8325, 2009.PubMedCrossRef Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317–8325, 2009.PubMedCrossRef
27.
Zurück zum Zitat Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14:2610–2622, 2000.PubMedCrossRef Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14:2610–2622, 2000.PubMedCrossRef
28.
Zurück zum Zitat Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156:299–313, 2002.PubMedCrossRef Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156:299–313, 2002.PubMedCrossRef
29.
Zurück zum Zitat Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, Nikiforova MN. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 18:2035–2041, 2011.PubMedCrossRef Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, Nikiforova MN. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 18:2035–2041, 2011.PubMedCrossRef
30.
Zurück zum Zitat Nose V. Familial non-medullary thyroid carcinoma: an update. Endocr Pathol 19:226–240, 2008.PubMedCrossRef Nose V. Familial non-medullary thyroid carcinoma: an update. Endocr Pathol 19:226–240, 2008.PubMedCrossRef
31.
Zurück zum Zitat Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 104:9001–9006, 2007.PubMedCrossRef Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 104:9001–9006, 2007.PubMedCrossRef
32.
Zurück zum Zitat Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol 21:16–24, 2010.PubMedCrossRef Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol 21:16–24, 2010.PubMedCrossRef
Metadaten
Titel
Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome
verfasst von
Daniel A. Winer
Shawn Winer
Lorne Rotstein
Sylvia L. Asa
Ozgur Mete
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2012
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9219-6

Weitere Artikel der Ausgabe 4/2012

Endocrine Pathology 4/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …